Omeza Raises $5.75MM in Second Capital Round

SARASOTA, Fla. - April 30, 2019 - PRLog -- Sarasota-based Omeza, LLC closed on its most recent funding round March 28, exceeding its $5MM goal by $0.75MM and attracting a line-up of distinguished board members in the process.

A medtech and consumer healthcare company, Omeza invited a select group of individuals to invest in its breakthrough technology which is initially aimed at healing and preventing chronic leg and foot ulcers. The funding will support its marketing of best-in-class alternatives to both rudimentary and "advanced" wound care treatments that are costly and often ineffective.

Currently launching the second of its core OmezaTM omega oil products, the company will focus on evidence generation this quarter, as well as building out its marketing, sales and logistics capacity. User feedback and use cases are stacking up favorably, as the company begins charting clinical trials.

A group of high net-worth individuals, all with ties to the Sarasota area, subscribed to the investment opportunity in a compressed due diligence period lasting only a few months. The Board agreed to keep the round open for up to 6 more months, with Omeza willing to accept an additional $1.25MM or a grand total of $7MM.

States founder Tom Gardner, "With intellectual property, regulatory approvals, scalable manufacturing capacity and management systems in place, the funds will be used for working capital to grow revenue."

With the close of this round came the appointment of a Board of Managers, comprised of investors who expressed interest in being active board members as part of their investment. Omeza's Board Chairman is Joel Morganroth, M.D., P.C., former CEO of (ERT) eResearch Technology Inc. Additional Board members are Ronald G. Gelbman, Member, Executive Committee Johnson & Johnson; Chairman, Pharmaceuticals and Diagnostics, Johnson & Johnson; Robert A. Essner, former Chairman and Chief Executive Officer of Wyeth; A.G. Lafley, former Chairman and CEO of Procter & Gamble; and Thomas Gardner, Omeza CEO and Founder and a veteran of Procter & Gamble, Johnson & Johnson and numerous medtech early stage companies.

The first Board of Managers meeting was held April 5 at Omeza's headquarters in downtown Sarasota.

About Omeza: Omeza (https://omeza.com/) is a medtech and consumer healthcare products company focused on skin, the largest organ in the human body and part of the integumentary vital organ system. Omeza's mission is to heal chronic wounds and prevent their recurrence. Omeza products are available for purchase by consumers on Amazon, and at selected independently owned pharmacies. Inquiries from medical and health professionals should be directed to info@omeza.com.